An 1H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia
Claudio Cerchione(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Vincenzo Martinelli(Federico II University Hospital), Sonia Ronconi(Istituti di Ricovero e Cura a Carattere Scientifico), Sara Bravaccini(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Michele Manfra(University of Basilicata), Giorgia Simonetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Fabrizio Pane(Federico II University Hospital), Marco Picardi(CEINGE Biotecnologie Avanzate Franco Salvatore (Italy)), Silvana Pedatella(University of Naples Federico II), Mattia Altini(Agenzia Sanitaria e Sociale Regionale), Mauro De Nisco(University of Basilicata), Lucio Catalano(University of Naples Federico II), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Giovanni Martinelli(University of Bologna), Vita Dora Iula(University of Naples Federico II), Novella Pugliese(University of Naples Federico II), Nicoletta Marra(Santobono Children's Hospital), Francesco Pagano(University of Salerno), Adele Bolognese(University of Naples Federico II), Andrea Ghelli Luserna di Rorà(Fondazione Pisa)
Cited by 2
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k